Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study

NCT03130452 is registered in ClinicalTrials.gov with Inje University as lead sponsor.

NCT NCT03130452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03130452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study
Lead sponsor
Inje University
Phase
Phase 4
Overall status
Completed
Start date
December 17, 2016
Completion date
May 31, 2019
Enrollment
423 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection